Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.

New diagnostic procedures and prognostic markers are continually being developed for a wide range of medical complaints. Medical institutions are therefore regularly faced with the decision as to whether to replace an existing procedure with a new one. The decision to adopt a new method is primarily based on diagnostic/predictive accuracy and cost-effectiveness, but this trade-off is not usually considered in a formal decision-theoretic way. The decision process for diagnostic procedures is complicated by the fact that diagnostic decisions are typically based on thresholding one or more continuous variables. Therefore, a formal decision process should account for uncertainty in the optimal threshold value for each diagnostic procedure. We here propose a Bayesian decision approach based on maximizing expected utility (incorporating accuracy and costs) with respect to diagnostic procedure and threshold level simultaneously. The Bayesian decision approach is illustrated via an application comparing the utility of different bone mineral density (BMD) measurements for determining the need for preventative treatment of osteoporotic hip fracture in elderly patients.

[1]  O. Johnell,et al.  The risk and burden of vertebral fractures in Sweden , 2004, Osteoporosis International.

[2]  Joseph A Johnston,et al.  Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia , 2007, BMC women's health.

[3]  Anthony O'Hagan,et al.  The probability of cost-effectiveness , 2002, BMC medical research methodology.

[4]  B. Muthén,et al.  A Bayesian approach to nonlinear latent variable models using the Gibbs sampler and the metropolis-hastings algorithm , 1998 .

[5]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[6]  D. Lindley The choice of sample size , 1997 .

[7]  J. Kanis,et al.  DIAGNOSIS OF OSTEOPOROSIS , 2016 .

[8]  J. Bernardo Statistical inference as a decision problem: the choice of sample size , 1997 .

[9]  Giovanni Parmigiani,et al.  Uncertainty and the value of diagnostic information, with application to axillary lymph node dissection in breast cancer , 2004, Statistics in medicine.

[10]  Robert Kane,et al.  Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women , 2005, Annals of Internal Medicine.

[11]  R Simon,et al.  Bayesian Design and Analysis of Active Control Clinical Trials , 1999, Biometrics.

[12]  Hua Jin,et al.  A Procedure for Determining Whether a Simple Combination of Diagnostic Tests May Be Noninferior to the Theoretical Optimum Combination , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  Lee R. Mobley,et al.  Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  Paul Kind,et al.  Measuring Population Health: A Comparison Of Three Generic Health Status Measures , 2003, Medical care.

[15]  Adrian F. M. Smith,et al.  Evidence-based medicine as Bayesian decision-making. , 2000, Statistics in medicine.

[16]  Anthony O'Hagan,et al.  Kendall's Advanced Theory of Statistics, volume 2B: Bayesian Inference, second edition , 2004 .

[17]  A O'Hagan,et al.  Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies , 2002, Statistical methods in medical research.

[18]  Marek Ancukiewicz,et al.  Decision Models in Clinical Recommendations Development : the Stroke Prevention Policy , 1996 .

[19]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[20]  Dimitris Fouskakis,et al.  Comparing Stochastic Optimization Methods for Variable Selection in Binary Outcome Prediction, With Application to Health Policy , 2008 .

[21]  S. Gabriel,et al.  Mortality, Disability, and Nursing Home Use for Persons with and without Hip Fracture: A Population‐Based Study , 2002, Journal of the American Geriatrics Society.

[22]  Hua Jin,et al.  Permutation test for non-inferiority of the linear to the optimal combination of multiple tests. , 2009, Statistics and Probability Letters.

[23]  M. Pepe The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[24]  Mu Zhu The Counter-intuitive Non-informative Prior for the Bernoulli Family , 2004 .

[25]  Magnus Johannesson,et al.  Swedish population health-related quality of life results using the EQ-5D , 2004, Quality of Life Research.

[26]  E. Arias,et al.  United States life tables, 2004. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[27]  Patrick S. Carroll Making Decisions (Second Edition). By D. V. Lindley. Wiley 1985. 207 pages. , 1986 .

[28]  A J Moskowitz,et al.  Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.

[29]  Peter Müller,et al.  Screening designs for drug development. , 2007, Biostatistics.

[30]  Anthony O'Hagan,et al.  INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA , 2002, International Journal of Technology Assessment in Health Care.

[31]  S. Gabriel,et al.  Direct Medical Costs Attributable to Osteoporotic Fractures , 2002, Osteoporosis International.

[32]  B W Brown,et al.  The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.

[33]  Stephen G. Walker,et al.  How many samples?: A Bayesian nonparametric approach , 2003 .

[34]  J. Kanis,et al.  Economic Evaluation of Interventions for Osteoporosis , 2002, Osteoporosis International.

[35]  O Johnell,et al.  Intervention thresholds for osteoporosis. , 2002, Bone.

[36]  A O'Hagan,et al.  A framework for cost-effectiveness analysis from clinical trial data. , 2001, Health economics.

[37]  R. G. Murray,et al.  Bayesian analysis of stress thallium-201 scintigraphy , 2004, European Journal of Nuclear Medicine.

[38]  D. Draper,et al.  Bayesian variable selection using cost-adjusted BIC, with application to cost-effective measurement of quality of health care , 2009, 0908.2313.

[39]  D K Stangl,et al.  Prediction and decision making using Bayesian hierarchical models. , 1995, Statistics in medicine.

[40]  Xiao-Hua Zhou,et al.  Statistical Methods in Diagnostic Medicine , 2002 .

[41]  Ego Seeman,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[42]  A O'Hagan,et al.  Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.

[43]  Rachael L. Fleurence,et al.  The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis , 2012, PharmacoEconomics.

[44]  Dimitris Fouskakis,et al.  A Case Study of Stochastic Optimization in Health Policy: Problem Formulation and Preliminary Results , 2000, J. Glob. Optim..

[45]  D R Shapiro,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[46]  Anthony O’Hagan,et al.  Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio , 2000, PharmacoEconomics (Auckland).

[47]  David Lindley,et al.  Decision analysis and bioequivalence trials , 1998 .

[48]  A. F. Smith,et al.  Exploratory thoughts on clinical trials with utilities. , 1998, Statistics in medicine.

[49]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[50]  T. Pham-Gia,et al.  On Bayesian analysis, Bayesian decision theory and the sample size problem , 1997 .

[51]  Dalene K Stangl,et al.  Bridging the gap between statistical analysis and decision making in public health research , 2005, Statistics in medicine.

[52]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[53]  Mu Zhu,et al.  The Counter-intuitive Non-informative Prior for the Bernoulli Family , 2004 .

[54]  D. Draper,et al.  Stochastic Optimization: a Review , 2002 .

[55]  T. M. Kashner,et al.  Survival experience of aged hip fracture patients. , 1989, American journal of public health.

[56]  Michael C. Nevitt,et al.  Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .

[57]  P. Müller Simulation Based Optimal Design , 2005 .

[58]  Andrew Gelman,et al.  Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .